Abstract
Dendritic cells (DCs) have traditionally been viewed as constituting an ‘information management’ system that functions solely to integrate a diverse array of incoming signals, in order to induce immune reactivity. In recent years, however, there has been a shift towards viewing these cells as key regulators in the orchestration of immunological tolerance, with increasing recognition that they are capable of suppressing T-cell responses depending on signalling processes and localised biochemical conditions. Indoleamine 2,3-dioxygenase (IDO) competent (IDO+) DCs are a subset of human DCs which are programmed to a tolerogenic state and play a vital role in establishing and maintaining a tumoursuppressing milieu. The expression of IDO in these DCs represents a key mechanism responsible for inducing the tolerogenic state. However, the mechanisms by which IDO becomes dysregulated in this subset of DCs have not yet been described. In this review, the function of IDO+ DCs within the cancer-tolerogenic milieu, as well as the signals responsible for expression of IDO in this subset, will be discussed.
Keywords: Cancer, dendritic cells, immune response, indoleamine 2, 3-dioxygenase, signalling pathways, tolerance
Current Cancer Drug Targets
Title:IDO+ DCs and Signalling Pathways
Volume: 13 Issue: 3
Author(s): Yue Wang, Bao-Hong Yang, Hui Li, Shui Cao, Xiu-Bao Ren and Jin-Pu Yu
Affiliation:
Keywords: Cancer, dendritic cells, immune response, indoleamine 2, 3-dioxygenase, signalling pathways, tolerance
Abstract: Dendritic cells (DCs) have traditionally been viewed as constituting an ‘information management’ system that functions solely to integrate a diverse array of incoming signals, in order to induce immune reactivity. In recent years, however, there has been a shift towards viewing these cells as key regulators in the orchestration of immunological tolerance, with increasing recognition that they are capable of suppressing T-cell responses depending on signalling processes and localised biochemical conditions. Indoleamine 2,3-dioxygenase (IDO) competent (IDO+) DCs are a subset of human DCs which are programmed to a tolerogenic state and play a vital role in establishing and maintaining a tumoursuppressing milieu. The expression of IDO in these DCs represents a key mechanism responsible for inducing the tolerogenic state. However, the mechanisms by which IDO becomes dysregulated in this subset of DCs have not yet been described. In this review, the function of IDO+ DCs within the cancer-tolerogenic milieu, as well as the signals responsible for expression of IDO in this subset, will be discussed.
Export Options
About this article
Cite this article as:
Wang Yue, Yang Bao-Hong, Li Hui, Cao Shui, Ren Xiu-Bao and Yu Jin-Pu, IDO+ DCs and Signalling Pathways, Current Cancer Drug Targets 2013; 13 (3) . https://dx.doi.org/10.2174/15680096113139990073
DOI https://dx.doi.org/10.2174/15680096113139990073 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Death and Growth Signals at the Plasma Membrane by Sphingomyelin Synthesis: Implications for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Finding Appropriate Signal Peptides for Secretory Production of Recombinant Glucarpidase: An <i>In Silico</i> Method
Recent Patents on Biotechnology Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?
Current Drug Targets High-Risk HPV/ErbB-2 Interaction on E-Cadherin/Catenin Regulation in Human Carcinogenesis
Current Pharmaceutical Design Dendrimer Based Formulation of Erlotiniib HCl: Development, Characterization and <i>In-Vitro</i> Evaluation
Pharmaceutical Nanotechnology Transmucosal Drug Delivery- An Overview
Drug Delivery Letters Chemoradiation for Oropharyngeal Carcinoma for Organ Preservation
Current Cancer Therapy Reviews Regulation of MET Receptor Signaling by SOCS1 and its Implications for Hepatocellular Carcinoma
Current Pharmaceutical Design Effect of the Bioactive Fraction of Argyreia speciosa Leaves Against Gastric Ulcer and Antioxidant Defence System in Rats
Current Traditional Medicine Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer
Current Signal Transduction Therapy Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers Vitamin D3 and Vitamin D3 Analogues as an Adjunct to Cancer Chemotherapy and Radiotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Specific Nutritional Supplement (Supportan<sup>®</sup>) in the Supportive Care of the Radio-Chemotherapy Treatment of Head and Neck Cancers: Biochemical Parameters. Preliminary Study
Endocrine, Metabolic & Immune Disorders - Drug Targets A Structure-Function Perspective of Jak2 Mutations and Implications for Alternate Drug Design Strategies: The Road not Taken
Current Medicinal Chemistry Comprehensive Review of Cancer Chemopreventive Agents Evaluated in Experimental Carcinogenesis Models and Clinical Trials
Current Medicinal Chemistry The Next Step in Voice Assessment: High-Speed Digital Endoscopy and Objective Evaluation
Current Bioinformatics Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma
Protein & Peptide Letters